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(pre-authorized) members and AAP guidelines for palivi-
zumab prophylaxis. Physicians were asked to treat ac-
cording to clinical judgement. We then compared PRH,
ALOS, and costs (PRH, drug, and administration) be-
tween prophylaxed (N  69) and non-prophylaxed (N 
136) high-risk children. PRH were defined based on ICD-
9-CM discharge codes for RSV infection, bronchiolitis,
pneumonia, bronchitis, asthma, and other abnormal res-
piratory conditions. Hospitalization costs were tallied at
$1500/day. RESULTS: Overall PRH rate and ALOS
were reduced from 35.2% and 12.9 days in the baseline
period to 25.9% (P  0.1) and 8.1 days (P  0.05) re-
spectively. Non-prophylaxed children consumed more re-
sources (31.6% PRH, 8.7 ALOS) than prophylaxed chil-
dren (14.5% PRH, 5.4 ALOS). Reductions from baseline
PRH and ALOS were significant in the treatment group
(P  0.05 for each). Drug and administration costs of
$286,725 saved $467,571 in expected costs had baseline
rates continued ($2281/high-risk member, $6776/immu-
nized member). CONCLUSIONS: Guideline dissemina-
tion and pre-authorizing RSV prophylaxis with palivi-
zumab in a high-risk Medicaid population is an effective
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The incidence of acute myeloid leukemia (AML) is grow-
ing among the elderly. However, data on the clinical out-
comes and costs of this form of cancer are sparse. OB-
JECTIVE: To estimate rates of mortality and hospitalization
costs in the first year following the diagnosis of AML
among US Medicare beneficiaries 65 years of age and
older. METHODS: This study was based on SEER-Medi-
care data files, which include a linkage between cancer
registry data and Medicare administrative claims data for
approximately 14% of cancer cases identified in 17 geo-
graphically diverse regions across the US. Patients ini-
tially diagnosed with AML between 1991 and 1993 were
identified from SEER registry data and followed for one
year. The use of chemotherapy was ascertained based on
DRGs, and ICD-9-CM diagnosis and procedure codes.
Costs of care were based on total Medicare hospital pay-
ments. RESULTS: A total of 1,391 patients with AML
were identified. In the year following diagnosis, only
27% of these patients underwent chemotherapy treat-
ment. The prognosis for AML was quite poor, with a me-
dian survival estimated to be 3 months (mean  SD: 5.2 
5.1), and over 75% of patients having died within one
year. The number of hospitalizations (mean  SD) dur-
ing the one-year follow-up was 1.95  1.50, with corre-
sponding Medicare inpatient payments of $23,670 
$26,583. Average Medicare hospital payments varied
only slightly by sex and race, and declined substantially
by age (due to poorer survival). Patients who underwent
chemotherapy had costs almost 3 times higher than those
of other patients, but also lived an average of 3 months
longer. CONCLUSION: AML among the elderly is asso-
ciated not only with a poor prognosis, but also with sub-
stantial inpatient costs over the relatively few remaining
months of life.
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